PubMed Health⌕ Search

PubMed · 17066193

Designer electrode interfaces simultaneously comprising three different metal nanoparticle (Au, Ag, Pd)/carbon microsphere/carbon nanotube composites: progress towards combinatorial electrochemistry.

Abstract

In this report gold, silver and palladium metal nanoparticles are separately supported on glassy carbon microspheres (GCM) using bulk electroless deposition techniques to produce three different materials labelled as GCM-Au, GCM-Ag and GCM-Pd respectively. These three materials are then combined together into a composite film on a glassy carbon (GC) electrode surface using multiwalled carbon nanotubes (MWCNTs). The MWCNTs serve to not only mechanically support this composite film as a "binder" but they also help to "wire up" each modified GCM to the underlying substrate. The intelligently designed structure of this electrode interface allows this single modified electrode to simultaneously behave as if it were a macrodisc electrode constructed of gold, silver or palladium, whilst using only a fraction of the equivalent amount of these precious metals. Furthermore this unique structure allows the possibility of combinatorial electrochemistry to be realised using a relatively facile electrode construction which avoids the problems of alloy formation, co-deposition and the formation of bimetallic species. For instance a mixture of several different analytes, which can each only be detected on a different specific substrate, can simultaneously be determined using one electrode in a single voltammetric experiment! Alternatively a substrate could undergo electrocatalytic reactions on one substrate, whilst the products, and hence the progress of this reaction, can be studied at a different substrate simultaneously at the same electrode surface. Proof-of-concept examples are presented herein and the designer electrode interface is shown to produce analytical responses to model target analytes such as hydrazine, bromide and thallium(I) ions that are comparable, if not better, than those obtained at metal macrodisc electrodes and even at other state-of-the-art nanoparticle modified electrodes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xuan Dai, Gregory G Wildgoose, Richard G Compton. 2006-09-04. Designer electrode interfaces simultaneously comprising three different metal nanoparticle (Au, Ag, Pd)/carbon microsphere/carbon nanotube composites: progress towards combinatorial electrochemistry.. https://doi.org/10.1039/b607774a

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗